Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310196 | 1.00 | PTGS2 (0.49) | PTGS2PTGS1ALPIPKMXIAP | |
| SCHEMBL28758664 | 0.97 | PTGS1 (0.47) | PTGS2PTGS1ALPIPKMXIAP | |
| SCHEMBL1945444 | 0.88 | SLC7A5 (0.48) | PTGS2SLC7A5CA12CA1CA2 | |
| SCHEMBL1832905 | 0.88 | SLC7A5 (0.48) | PTGS2SLC7A5CA12CA1CA2 | |
| SCHEMBL6368998 | 0.87 | ALPI (0.61) | PTGS1ALPIPKMXIAPSLC7A5 | |
| SCHEMBL3307185 | 0.87 | PTGS1 (0.46) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL13396369 | 0.87 | SLC7A5 (0.47) | PTGS2SLC7A5CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL3303742 | 0.86 | PTGS1 (0.45) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL14095415 | 0.85 | ALPI (0.59) | PTGS1ALPIPKMXIAPSLC7A5 | |
| SCHEMBL15590174 | 0.85 | ALPI (0.59) | PTGS1ALPIPKMXIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125695-B1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SCIENCE IRELAND (IE) | 2016-10-26 | — | — | EP | disclosed |
| US-9266820-B2 | Nitric oxide donor compounds | NICOX SCIENCE IRELAND (IE) | 2016-02-23 | — | — | US | disclosed |
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2014-09-25 | — | — | US | disclosed |
| US-20110052674-A1 | ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | PTGS2 15/4885PTGS1 8/4885ALPI 805/4885 |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | PTGS2 12/4885PTGS1 7/4885ALPI 656/4885 |
| US-20110052674-A1 | ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | AGTR1, AGTR2, AGT | PTGS2 255/4885PTGS1 329/4885ALPI 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.